Trial Profile
Coordinated High Dose Interleukin-2 (Aldesleukin, Proleukin) and Pembrolizumab (Anti-PD1, Keytruda) for Therapy of Metastatic Kidney Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 Apr 2023
Price :
$35
*
At a glance
- Drugs Aldesleukin (Primary) ; Pembrolizumab (Primary)
- Indications Renal cancer
- Focus Therapeutic Use
- 12 Apr 2023 Planned End Date changed from 1 Dec 2023 to 1 Apr 2024.
- 10 Apr 2023 Planned End Date changed from 1 Mar 2023 to 1 Dec 2023.
- 25 Apr 2022 Planned End Date changed from 1 Mar 2022 to 1 Mar 2023.